BG
NVCR icon

Bellevue Group’s NovoCure NVCR Stock Holding History

Bellevue Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,000
Closed -$660K – 170
2022
Q4 		$660K Buy
+9,000
New +$677K 0.01% 149
2022
Q3 		– Sell
-25,300
Closed -$1.76M – 181
2022
Q2 		$1.76M Buy
25,300
+16,800
+198% +$1.27M 0.02% 133
2022
Q1 		$704K Buy
+8,500
New +$626K 0.01% 153

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Bellevue Group's NVCR Position: Q1 2023 in Review

Bellevue Group sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 9,000 shares — an estimated $660K sold.

Bellevue Group first reported a position in NVCR in Q1 2022 and held it in 3 quarters. The position peaked at $1.76M in Q2 2022. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

  • Bellevue Group reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
  • Bellevue Group sold 9,000 NovoCure shares in Q1 2023, an estimated $660K.
  • Bellevue Group first reported a position in NovoCure in Q1 2022 and held it in 3 quarters.
  • Bellevue Group's NovoCure position peaked at $1.76M in Q2 2022.
  • 295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.